China Finds Illegitimate Invoices In 11,000 Pharma
This article was originally published in PharmAsia News
Executive Summary
In a joint nine-month countrywide investigation involving nearly 7,600 health institutes and some 30,000 pharma organizations, Chinese authorities have discovered 35.2 illegal invoices in around 11,000 institutes and ordered fines and taxes repayments totaling RMB 2.52 billion ($408 million).
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.